Recombinant anti-IL-17A humanized monoclonal antibody
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Recombinant anti-IL-17A humanized monoclonal antibody, covering 2022-11-08 to 2025-03-11. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis [Phase 3]